NEW YORK CITY, NY / ACCESS Newswire / May 30, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE:OGN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/organon-co-class-action.

NEW YORK CITY, NY / ACCESS Newswire / May 30, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ:VTRS) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/viatris-inc.

NEW YORK, NY / ACCESS Newswire / May 30, 2025 / If you suffered a loss on your Treace Medical Concepts, Inc. (NASDAQ:TMCI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/treace-medical-concepts-inc-lawsuit-submission-form-2?prid=151047&wire=1&utm_campaign=30 or contact Joseph E. Levi, Esq.

Hello Group is shifting focus to high-return paying users and international expansion, which may reduce user count but boost future free cash flow. Despite short-term revenue declines and user base contraction, the stock trades at attractive valuation multiples and appears undervalued. Ongoing share repurchases, a strong broadcaster network, and new app launches support my bullish outlook on MOMO.

Advisors and investors seeking out alternatives for portfolio diversification shouldn't overlook global macro hedge fund strategies. With a history of reduced volatility, performance enhancements, and loss mitigation, the strategy is a diversifier worth adding to portfolios, particularly when done through an ETF.

This Dogs of the Dow list from DowJones&Co appeared January, 2025 on YCharts, and Dogs of The Dow websites. Here is your June update from that data. 28 of 30 current Dow-listed-stocks pay dividends. As of 5/28/25, the top-ten ranged 2.64%-6.26% by annual-yield, and another top-ten ranged 18.06%-46.15% in broker-estimated target-price-upsides. Analyst-estimated top-ten net-gains from Dow's June dividend dogs ranged 21.02%-45.96% from HD, AMZN, CVX, MSFT, MRK, NKE, CRM, DIS, UNH, and NVDA, per YCharts.

A surge in the price is far outshining gains for industrial metals such as zinc and copper.

Nvidia's Q1 FY26 results were remarkable, and I consider the company's ongoing strength to be directly tied to the pioneering leadership and vision of Jensen Huang. In the face of all challenges, including early failures and multiple cycles in the market, Nvidia has risen to be the greatest AI company in the world. AI is the U.S. national anthem of success, and this anthem is spreading across the world. Nvidia is the heart of the revolution positioned for a 30% 12-month return.

NEW YORK, NY / ACCESS Newswire / May 30, 2025 / If you suffered a loss on your Bitfarms Ltd. (NASDAQ:BITF) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bitfarms-ltd-lawsuit-submission-form?prid=151045&wire=1&utm_campaign=10 or contact Joseph E.

NEW YORK , May 30, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Treace Medical Concepts, Inc. (NASDAQ: TMCI) between May 8, 2023 and May 7, 2024, both dates inclusive (the "Class Period"), of the important June 10, 2025 lead plaintiff deadline. So what: If you purchased Treace Medical securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

PFS in Phase 3 HARMONi study, using ivonescimab + chemotherapy to treat patients with EGFR 2nd-line NSCLC, was met with statistical significance, but OS was not. OS data not being met in a statistically significant manner puts doubt on company's ability to file a BLA of ivonescimab for the treatment of patients with EGFR 2nd-line NSCLC. The global non-small cell lung cancer therapeutics market is expected to reach $37.49 billion by 2035.

LOS ANGELES--(BUSINESS WIRE)--URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm.

NEW YORK , May 30, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Canopy Growth Corporation (NASDAQ: CGC) between May 30, 2024 and February 6, 2025, both dates inclusive (the "Class Period"), of the important June 3, 2025 lead plaintiff deadline. So What: If you purchased Canopy Growth securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NEW YORK, NY / ACCESS Newswire / May 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of UroGen Pharma Ltd. ("UroGen Pharma Ltd.

A Skechers USA shareholder has sued the footwear maker for more details about its $9.4 billion buyout by private equity firm 3G Capital, saying the decision by Skechers' founder and controlling shareholder to sell raises "red flags."

Tesla CEO Elon Musk deflected a reporter's attempt to ask him about a New York Times article detailing his alleged drug use during President Donald Trump's campaign last year and drama involving the mothers of his multiple children. The Times earlier Friday detailed what it said was Musk's consumption of the anesthetic ketamine that "went well beyond occasional uses," and his alleged use of Ecstasy and psychedelic mushrooms.

HSBC is reportedly winding down its business banking unit in the U.S. as it sharpens its focus on other markets. As it disbands the business banking unit, which served small and medium-sized businesses (SMBs) in the U.S.

There has been a significant pullback in the retail sector recently, both in terms of stock prices and the United States economy, marked by slower consumer and business spending. The primary reason for this behavior and dynamic is that the recent trade tariffs implemented by President Trump may have spooked some in the sector, as it is heavily reliant on imports from other nations.

ROOT surges past 200-day SMA as YTD gains hit 72.6%, backed by margin growth, tech focus and strong ROE despite trading at a premium.

TRV to sell most of its Canadian insurance business to Definity for $2.4B, aiming to boost shareholder value and streamline operations.